filmov
tv
J&J Single-Dose Vaccine Prevents 100% of Covid Hospitalizations, Deaths
Показать описание
Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign.
In a study of more than 44,000 people, the vaccine prevented 66% of moderate to severe cases of Covid-19, according to a company statement Friday. And it was particularly effective at stopping severe disease, preventing 85% of severe infections and 100% of hospitalizations and deaths.
“If you can prevent severe disease in a high percentage of individuals, that will alleviate so much of the stress and human suffering” of the pandemic, said Anthony Fauci, the top U.S. infectious-disease official, at a briefing on the results with company and government officials.
Based on the result, J&J plans to file with the U.S. Food and Drug Administration for an emergency-use authorization next week. The drug giant’s top scientist said this month he expects a clearance in March, and that it would have product ready to ship then. The company didn’t specify how much of the vaccine would be available immediately, though it reaffirmed that the U.S. would receive 100 million doses by the end of June.
Shares of J&J declined 3.9% to $162.63 at 9:59 a.m. in New York on Friday. Investors had been hoping for an overall efficacy number of 80% or higher, according to Wall Street analysts.
If cleared, J&J’s vaccine could go a long way toward ending the pandemic. Competing vaccines from Moderna Inc. and Pfizer Inc. have generated stronger overall efficacy rates of more than 90%, but require two shots to be given before their full benefits take hold. J&J’s shot also can be kept in a refrigerator for three months, while those from Pfizer and Moderna must be kept frozen.
“This is a single shot that can be given easily, it protects completely from that which we fear, having to go to the emergency room or a hospital,” said Mathai Mammen, head of global research and development for J&J’s pharmaceutical division, in an interview. “It’s going to change the nature of the disease.”
White House Press Secretary Jen Psaki said in a briefing Friday that President Joe Biden is encouraged by the “positive data” from J&J and believes that “now is the time for the FDA to do its job evaluating the safety and efficacy of the vaccine.”
Concerns about keeping second doses of the current shots on hand have complicated the push to get as many people as possible inoculated. Some countries have chosen to spread out the time between doses to address the problem, at the risk of diminishing their effectiveness.
The rise of new coronavirus variants has added to the pressure to get immunizations moving faster. The J&J trial was conducted around the globe, including at dozens of clinical-trial sites in hot spots such as South Africa and Brazil where new variants have caused infections to rise.
J&J’s results produced more evidence that the variants will be harder to ward off. In the U.S., where mutations aren’t thought to be as widespread, the vaccine was 72% effective. But in South Africa, where a variant called B.1.351 is circulating widely, it was only 57% effective. And the shot was 66% effective in Latin America.
Nonetheless, J&J’s vaccine is likely to give countries around the world a powerful new tool to fight a virus that has infected more than 101 million people and killed 2.2 million worldwide.
If confirmed, the results suggest people could get one dose of the vaccine to provide initial protection against severe consequences, allowing them to return to their pre-pandemic lives. Then, if needed, they could later take a booster shot J&J is testing in other large, late-stage trials that could produce results before year-end.
Protection was consistent across race, age groups, including those over the age of 60, and regions. J&J’s Mammen added that the shot appears to generate immunity that ramps up and sustains itself over time.
Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
Connect with us on…
In a study of more than 44,000 people, the vaccine prevented 66% of moderate to severe cases of Covid-19, according to a company statement Friday. And it was particularly effective at stopping severe disease, preventing 85% of severe infections and 100% of hospitalizations and deaths.
“If you can prevent severe disease in a high percentage of individuals, that will alleviate so much of the stress and human suffering” of the pandemic, said Anthony Fauci, the top U.S. infectious-disease official, at a briefing on the results with company and government officials.
Based on the result, J&J plans to file with the U.S. Food and Drug Administration for an emergency-use authorization next week. The drug giant’s top scientist said this month he expects a clearance in March, and that it would have product ready to ship then. The company didn’t specify how much of the vaccine would be available immediately, though it reaffirmed that the U.S. would receive 100 million doses by the end of June.
Shares of J&J declined 3.9% to $162.63 at 9:59 a.m. in New York on Friday. Investors had been hoping for an overall efficacy number of 80% or higher, according to Wall Street analysts.
If cleared, J&J’s vaccine could go a long way toward ending the pandemic. Competing vaccines from Moderna Inc. and Pfizer Inc. have generated stronger overall efficacy rates of more than 90%, but require two shots to be given before their full benefits take hold. J&J’s shot also can be kept in a refrigerator for three months, while those from Pfizer and Moderna must be kept frozen.
“This is a single shot that can be given easily, it protects completely from that which we fear, having to go to the emergency room or a hospital,” said Mathai Mammen, head of global research and development for J&J’s pharmaceutical division, in an interview. “It’s going to change the nature of the disease.”
White House Press Secretary Jen Psaki said in a briefing Friday that President Joe Biden is encouraged by the “positive data” from J&J and believes that “now is the time for the FDA to do its job evaluating the safety and efficacy of the vaccine.”
Concerns about keeping second doses of the current shots on hand have complicated the push to get as many people as possible inoculated. Some countries have chosen to spread out the time between doses to address the problem, at the risk of diminishing their effectiveness.
The rise of new coronavirus variants has added to the pressure to get immunizations moving faster. The J&J trial was conducted around the globe, including at dozens of clinical-trial sites in hot spots such as South Africa and Brazil where new variants have caused infections to rise.
J&J’s results produced more evidence that the variants will be harder to ward off. In the U.S., where mutations aren’t thought to be as widespread, the vaccine was 72% effective. But in South Africa, where a variant called B.1.351 is circulating widely, it was only 57% effective. And the shot was 66% effective in Latin America.
Nonetheless, J&J’s vaccine is likely to give countries around the world a powerful new tool to fight a virus that has infected more than 101 million people and killed 2.2 million worldwide.
If confirmed, the results suggest people could get one dose of the vaccine to provide initial protection against severe consequences, allowing them to return to their pre-pandemic lives. Then, if needed, they could later take a booster shot J&J is testing in other large, late-stage trials that could produce results before year-end.
Protection was consistent across race, age groups, including those over the age of 60, and regions. J&J’s Mammen added that the shot appears to generate immunity that ramps up and sustains itself over time.
Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
Connect with us on…
0:01:22
J&J Single-Dose Vaccine Prevents 100% of Covid Hospitalizations, Deaths
0:02:16
VERIFY: Should people turn down the single dose Johnson & Johnson vaccine and wait for Moderna, ...
0:02:37
FDA Panel Endorses Johnson & Johnson’s Single-Dose COVID-19 Vaccine | TODAY
0:05:59
What’s Different About the Johnson & Johnson COVID-19 Vaccine?
0:03:04
J&J single-shot Covid vaccine begins shipping after FDA, CDC approval
0:07:56
J&J Covid-19 Vaccine Is 66% Effective in Global Clinical Trial
0:05:19
Johnson & Johnson Could Begin Distribution of Covid Vaccine by Monday
0:02:24
FDA finds J&J vaccine 'safe' and 'effective'
3:08:40
April 23, 2021 ACIP Meeting - Janssen COVID-19 vaccine
0:03:49
Johnson & Johnson vaccine effective against COVID-19 variants l GMA
0:06:26
First One-Shot Covid Vaccine from Johnson & Johnson Proves Effective: Study
0:03:59
J&J Covid vaccine starts shipping after receiving emergency use authorization
3:13:31
CDC recommends US to resume use of J&J vaccine
0:10:14
Coronavirus vaccine: J&J requests emergency use authorization, plus a look at vaccine inequality
0:01:35
J&J files for U.S. COVID-19 vaccine authorization
0:04:42
FDA: One-Dose Johnson & Johnson Covid Vaccine Is Safe And Effective | The 11th Hour | MSNBC
0:04:40
Single Covid vaccine dose is the best way to alleviate strain on health services, expert says
0:05:29
FDA Issues Warning About J&J Covid Vaccine
0:02:04
Biden To Announce Purchase Of 100 Million Additional J&J Vaccine Doses | Stephanie Ruhle | MSNBC
0:01:24
J&J Vaccine: Six Cases of Rare Blood Clot Disorder Found in U.S.
0:02:39
Here's what makes the J&J vaccine different other than the one dose
0:06:36
What we know about Johnson & Johnson vaccine being 'paused' in Iowa
0:01:55
No, you should not skip the Johnson & Johnson vaccine in favor of other options | VERIFY
0:05:14
Coronavirus vaccine: Johnson & Johnson's one and done approach is a game changer: Physician
Комментарии